170
Participants
Start Date
March 28, 2018
Primary Completion Date
September 30, 2025
Study Completion Date
September 30, 2025
Apelin
Apelin is an endogenous peptide that activate a single G-protein couple receptor. Apelin inhibits insulin secretion, decreases glucose levels and increases insulin sensitivity.
Relaxin
Relaxin is RLN2 encoded endogenous peptide hormone, which binds to G protein coupled receptor RXFP1.
Normal saline
Vehicle
Verapamil
NO independent challenge agent
LN Monomethyl arginine
Basal NO synthase inhibitor
Addenbrooke's Hospital, Cambridge
Collaborators (2)
University of Cambridge
OTHER
AstraZeneca
INDUSTRY
MedImmune LLC
INDUSTRY
Cambridge University Hospitals NHS Foundation Trust
OTHER